

Time matters: The potential of rapid-acting antidepressants in treatment-resistant depression

Industry session financially supported by GH Research during the 38th ECNP Congress.

🕒 **Sunday 12 October 2025**
08:40 – 10:00
📍 **Elicium 2**

Programme Outline

Join us as we discuss the potential of rapid-acting antidepressants in treatment-resistant depression (TRD). This Satellite Symposium will explore current clinical practice treatment pathways, mechanisms of psychedelic molecules including mebufotenin, and recent clinical data on the use of rapid-acting antidepressants in TRD.

Session ID:

ISS07

Session type:

Industry Satellite Symposium

Faculty



CHAIRPERSON

Michael E. Thase


Professor of Psychiatry,
Department of Psychiatry of the
Perelman School of Medicine,
University of Pennsylvania,
Corporal Michael J. Crescenz
Veterans Affairs Medical Center,
Philadelphia, U.S.A.



SPEAKER

Lisa Harding

Assistant Clinical Professor,
Yale Department of Psychiatry.
Medical Director,
Mood Institute,
Connecticut, U.S.A.



SPEAKER

Johannes G. Ramaekers

Professor of Psychopharmacology
and Behavioural Toxicology,
Faculty of Psychology and
Neuroscience,
Maastricht University,
Netherlands



SPEAKER

Wiesław J. Cubała

Professor of Psychiatry,
Department of Psychiatry,
Medical University of Gdańsk,
Poland



**Scan For More
Information**